Ranjan Dohil

This inventor holds 34 USPTO granted patents and 8 published patent applications, plus 5 CIPO patents and 6 EPO patents, primarily in Respiratory Treatments. Top assignees: University of California, Meritage Pharma, Inc., Horizon Orphan LLC. Active years: 2011-2026.

USPTO Granted Patents = 34 (Patent Applications = 8)

% Patents Active = 97.1

CIPO Patents = 5 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 10)

Average Co-Inventor Count = 2.3

ph-index = 10

Forward Citations = 251(Granted Patents)

Company Filing History:

33 out of 15,964

University of California

patents

5 out of 9

Meritage Pharma, Inc.

where one patent can have more than one assignee

Years Active: 2011-2026

Loading Chart...

Areas of Expertise:

Cysteamine

Eosinophilic Disorders

NASH

Topical Corticosteroids

Budesonide

Delayed Release

Respiratory Diseases

Amino-Thiol Compounds

Inflammatory Diseases

Gastrointestinal Tract

Enterically Coated

Amino-Disulfide Compounds

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12576051 - Methods and composition for treating respiratory obstructive diseases (2026-03-17),

2. 12391643 - Substituted amino-thiol and amino-disulfide compounds, and uses thereof (2025-08-19),

3. 12268777 - Compositions and methods for treating eosinophilic disorders (2025-04-08),

4. 11576871 - Formulations of cysteamine and cystamine (2023-02-14),

5. 11547664 - Compositions and methods for treating eosinophilic disorders (2023-01-10),

6. 11413296 - Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract (2022-08-16),

7. 11311507 - Enterically coated cysteamine, cystamine and derivatives thereof (2022-04-26),

8. 11197822 - Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract (2021-12-14),

9. 11090279 - Delayed release cysteamine bead formulation, and methods of making and using same (2021-08-17),

10. 10537528 - Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine compounds (2020-01-21),

11. 10485774 - Enterically coated cysteamine, cystamine and derivatives thereof (2019-11-26),

12. 10307386 - Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products (2019-06-04),

13. 10272037 - Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract (2019-04-30),

14. 9925158 - Enterically coated cysteamine, cystamine and derivatives thereof (2018-03-27),

15. 9925157 - Enterically coated cysteamine, cystamine and derivatives thereof (2018-03-27),

Title: **Ranjan Dohil: Innovator in Pharmaceutical Formulations**

Introduction

Ranjan Dohil is a renowned inventor based in San Diego, CA, with an impressive portfolio of 31 patents. His work primarily focuses on innovative pharmaceutical formulations that aim to address various health disorders, particularly those related to eosinophilic diseases.

Latest Patents

Among his latest contributions to the field are significant patents concerning formulations of cysteamine and cystamine. These formulations include enteric coatings and compositions aimed at treating diseases and disorders manageable with cysteamine. Additionally, he has developed methods and compositions specifically for the treatment of eosinophilic disorders, including eosinophilic esophagitis, thus advancing therapeutic options for affected patients.

Career Highlights

Ranjan has had a notable career, working at prestigious institutions such as the University of California and Meritage Pharma, Inc. His involvement in these organizations has played a pivotal role in bringing his innovative ideas to fruition, leading to the successful development of critical medical formulations.

Collaborations

Throughout his career, Ranjan has collaborated with respected colleagues, including Jerry Schneider and Seema S. Aceves. These partnerships have contributed to a collaborative environment that fosters creativity and innovation in tackling complex medical issues.

Conclusion

Ranjan Dohil’s contributions to the field of pharmaceutical formulations have been significant, as demonstrated by his extensive patent portfolio. His work continues to influence the treatment landscape for eosinophilic disorders and solidifies his status as a leading innovator in the industry.